Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia

Vascular Cell

Volumn 4, Issue , 2012, Pages

  Govindarajan, Baskaran ^a   Willoughby, Laura ^b   Band, Hamid ^b   Curatolo, Adam S ^c   Veledar, Emir ^a   Chen, Suephy ^a   Bonner, Michael Y ^a   Abel, Martin Garrido ^a   Moses, Marsha A ^c   Arbiser, Jack L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; MATRIX METALLOPROTEINASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE B; RAPAMYCIN; TUBERIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INACTIVATION; HETEROZYGOTE; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SARCOMA; SKIN TUMOR; TUBEROUS SCLEROSIS; TUMOR CELL LINE;

ANIMALIA;

EID: 84866057854     PISSN: None     EISSN: 2045824X     Source Type: Journal    
DOI: 10.1186/2045-824X-4-11     Document Type: Article

References (25)

1. Inflammatory processes in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex. Boer K, Jansen F, Nellist M, Redeker S, van den Ouweland AM, Spliet WG, van Nieuwenhuizen O, Troost D, Crino PB, Aronica E, Epilepsy Res 2008 78 7 21 10.1016/j.eplepsyres.2007.10.002 18023148 (Pubitemid 350296774)
2. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. El-Hashemite N, Zhang H, Henske EP, Kwiatkowski DJ, Lancet 2003 361 1348 1349 10.1016/S0140-6736(03)13044-9 12711473 (Pubitemid 36514870)
3. Platelet-derived growth factor-induced p42/44 mitogen-activated protein kinase activation and cellular growth is mediated by reactive oxygen species in the absence of TSC2/tuberin. Finlay GA, Thannickal VJ, Fanburg BL, Kwiatkowski DJ, Cancer Res 2005 65 10881 10890 10.1158/0008-5472.CAN-05-1394 16322235 (Pubitemid 41713356)
4. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, Yeung RS, Walker CL, Noonan D, Kwiatkowski DJ, Chou MM, Panettieri RA, Krymskaya VP, J Biol Chem 2002 277 30958 30967 10.1074/jbc.M202678200 12045200 (Pubitemid 34970798)
5. The evolutionarily conserved TSC/Rheb pathway activates Notch in tuberous sclerosis complex and Drosophila external sensory organ development. Karbowniczek M, Zitserman D, Khabibullin D, Hartman T, Yu J, Morrison T, Nicolas E, Squillace R, Roegiers F, Henske EP, J Clin Invest 2010 120 93 102 10.1172/JCI40221 20038815
6. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis. Kwiatkowski DJ, Cancer Biol Ther 2003 2 471 476 14614311
7. Measurements of TSC2 GAP Activity Toward Rheb. Li Y, Inoki K, Vikis H, Guan KL, Methods Enzymol 2005 407 46 54 (Pubitemid 43815937)
8. Regulation of TSC2 by 14-3-3 binding. Li Y, Inoki K, Yeung R, Guan KL, J Biol Chem 2002 277 44593 44596 10.1074/jbc.C200510200 12364343 (Pubitemid 36159047)
9. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP, Cell 2005 121 179 193 10.1016/j.cell.2005.02.031 15851026 (Pubitemid 40546387)
10. Akt regulates growth by directly phosphorylating Tsc2. Potter CJ, Pedraza LG, Xu T, Nat Cell Biol 2002 4 658 665 10.1038/ncb840 12172554 (Pubitemid 34993701)
11. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D, Nat Cell Biol 2003 5 578 581 10.1038/ncb999 12771962 (Pubitemid 36781094)
12. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN, N Engl J Med 2008 358 140 151 10.1056/NEJMoa063564 18184959
13. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR, Ann Neurol 2006 59 490 498 10.1002/ana.20784 16453317 (Pubitemid 43358069)
14. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG, Cancer Cell 2003 4 147 158 10.1016/S1535-6108(03)00187-9 12957289 (Pubitemid 37045363)
15. Functional tyrosine kinase inhibitor profiling: a generally applicable method points to a novel role of platelet-derived growth factor receptor-beta in tuberous sclerosis. Arbiser JL, Govindarajan B, Bai X, Onda H, Kazlauskas A, Lim SD, Amin MB, Claesson-Welsh L, Am J Pathol 2002 161 781 786 10.1016/S0002-9440(10)64237-X 12213705 (Pubitemid 34988364)
16. Transgenic expression of dominant negative tuberin through a strong constitutive promoter results in a tissue-specific tuberous sclerosis phenotype in the skin and brain. Govindarajan B, Brat DJ, Csete M, Martin WD, Murad E, Litani K, Cohen C, Cerimele F, Nunnelley M, Lefkove B, Yamamoto T, Lee C, Arbiser JL, J Biol Chem 2005 280 5870 5874 15576369 (Pubitemid 40280069)
17. Malignant transformation of human cells by constitutive expression of platelet-derived growth factor-BB. Govindarajan B, Shah A, Cohen C, Arnold RS, Schechner J, Chung J, Mercurio AM, Alani R, Ryu B, Fan CY, Cuezva JM, Martinez M, Arbiser JL, J Biol Chem 2005 280 13936 13943 10.1074/jbc.M500411200 15695519 (Pubitemid 40517294)
18. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, Griffin JD, Kwiatkowski DJ, J Clin Invest 2007
19. Down-regulation of MMP-2 expression due to inhibition of receptor tyrosine kinases by imatinib and carboplatin in HNSCC. Schultz JD, Rotunno S, Erben P, Sommer JU, Anders C, Stern-Straeter J, Hofheinz RD, Hormann K, Sauter A, Oncol Rep 2011 25 1145 1151 21249321
20. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells. Lee PS, Tsang SW, Moses MA, Trayes-Gibson Z, Hsiao LL, Jensen R, Squillace R, Kwiatkowski DJ, Am J Respir Cell Mol Biol 2010 42 227 234 10.1165/rcmb.2009-0050OC 19395678
21. MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development. Li S, Takeuchi F, Wang JA, Fuller C, Pacheco-Rodriguez G, Moss J, Darling TN, J Exp Med 2005 202 617 624 10.1084/jem.20042469 16129702 (Pubitemid 41248413)
22. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Frias MA, Thoreen CC, Jaffe JD, SCHRODER W, Sculley T, Carr SA, Sabatini DM, Curr Biol 2006 16 1865 1870 10.1016/j.cub.2006.08.001 16919458 (Pubitemid 44354144)
23. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR, Cancer Res 2005 65 7052 7058 10.1158/0008-5472.CAN-05- 0917 16103051 (Pubitemid 41161231)
24. Urinary biomarkers predict brain tumor presence and response to therapy. Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA, Clin Cancer Res 2008 14 2378 2386 10.1158/1078-0432.CCR-07-1253 18413828 (Pubitemid 351551071)
25. Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo. Bhandarkar SS, Bromberg J, Carrillo C, Selvakumar P, Sharma RK, Perry BN, Govindarajan B, Fried L, Sohn A, Reddy K, Arbiser JL, Clin Cancer Res 2008 14 5743 5748 10.1158/1078-0432.CCR-08-0405 18794083